Here, we apply quantitative proteomic analyses in paired, longitudinal primary multiple myeloma samples and identify CDK6 upregulation as a non-genetic resistance mechansim for IMiDs in multiple myeloma that can be overcome by pharmacologic intervention. Here, CDK6 is linked to plasma cell myeloma.